Full Program

The San Antonio Breast Cancer Symposium® “An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” The San Antonio Breast Cancer Symposium® is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against brea

Read the full article here

Source: sabcs.org

Categories: Oncologists1, General Medicine News

Tags: SABCS24

Tweets with this article

The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes: Melissa B. Davis will address this topic in a plenary lecture at #SABCS24 (December 10-13). Learn more: https://t.co/9dlYrf2a6c @MeliD32 https://t.co/KDJobN6OUO

Multimodal treatment of glioblastoma with multiple lesions – a multi-center retrospective analysis

Journal of Neuro-Oncology – The presence of multiple localizations (ML) in glioblastoma is rare and associated with perceived poor prognosis. The aim of this study…

Journal of Neuro-Oncology November 27, 2024

Building Upon an “Era of Therapeutic Refinement” in Pancreatic Cancer

Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.

Cancer Network November 27, 2024

CNSide Can Aid Diagnosis, Management of Leptomeningeal Metastases

CNSide can aid the diagnosis and management of leptomeningeal metastases in patients with cancer, a new study suggests.

CancerTherapyAdvisor November 27, 2024

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

OncLive.com November 27, 2024

Aneuploid Cells in Normal Breast Tissue Challenge Cancer Paradigms

Normal breast tissue harbors rare populations of aneuploid cells, displaying genetic changes often associated with invasive breast cancer—a finding that challenges the reliability of genomic…

Cancer Discovery November 27, 2024

Tumor heterogeneity and cooperating cancer hallmarks driven by divergent EMT programs

Abstract. Epithelial-to-mesenchymal transition (EMT) is known to play roles in orchestrating cellular plasticity across many physiological and pathological contexts. Partial EMT, wherein cells maintain both…

Cancer Research November 27, 2024

As Trump’s second term nears, Republican support for NIH is at a low point By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research – The Cancer Letter

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…

The Cancer Letter November 27, 2024

ASH in a Flash – Artificial Intelligence in Hematology: From Generative AI to Ethics & Applications

#ASHinaFlash, your fast track to essential #ASH24 content! Get expert highlights of must-see sessions and quick takes on the latest #hematology breakthroughs…

ASH November 27, 2024

FDA Grants Fast Track Designation to LBS-007 in AML

LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.

Targeted Oncology November 27, 2024

Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

This was a phase 2 trial of all-trans retinoic acid plus arsenic trioxide with or without gemtuzumab ozogamicin in acute promyelocytic leukemia, in which patients…

ACS Journal Cancer November 27, 2024

Related Articles